Vildagliptin: a new oral treatment for type 2 diabetes mellitus

References

• AhrénBFoleyJE2008The islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract Suppl15981418269436
   PubMedGoogle Scholar
• AhrénBLandin-OlssonMJanssonP2004Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces gluca-gon levels in type 2 diabetesJ Clin Endocrinol Metab8920788415126524
   PubMed Web of Science ®Google Scholar
• AhrénBPaciniGFoleyJESchweizerA2005Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 yearDiabetes Care2819364016043735
   PubMed Web of Science ®Google Scholar
• AmoriRLauJPittasA2007Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA29819420617622601
   PubMed Web of Science ®Google Scholar
• AzumaKRádikováZMancinoJ2008Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab934596418042650
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJ2006Therapeutic approaches to preserve islet cell mass in type 2 diabetesAnnu Rev Med572658116409149
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonC2007The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab9212495517244786
   PubMed Web of Science ®Google Scholar
• BlondeLWogenJKreilickCSeymourAA2003Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metforminDiabetes Obes Metab54243114617228
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteECohenSE2008Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab10829018034842
   PubMed Web of Science ®Google Scholar
• BosiEByiersSRCohenSE2007bVildagliptin significantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin [abstract]Diabetes56suppl 1A139Abstract 521-P.
   Google Scholar
• BosiECamisascaRPColloberC2007aEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care30890517277036
   PubMed Web of Science ®Google Scholar
• BurkeyBFRussellMWangK2006Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9Diabetologia49suppl 1477Abstract 0788
   Google Scholar
• D’AlessioDWatsonCEHeY2006Restoration of an acute insulin response to glucose (AIRg) in drug naïve patients with type 2 diabetes (T2DM) by 3-month treatment with vildagliptinDiabetes55suppl 1A108Abstract 454-P
   Google Scholar
• DeaconCFCarrRDHolstJJ2008DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetesFront Biosci1317809417981667
   PubMed Web of Science ®Google Scholar
• DeaconCF2004Therapeutic strategies based on glucagon-like peptide-1Diabetes532181915331525
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerA2007Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res392182317373638
   PubMed Web of Science ®Google Scholar
• DruckerDJ2006The biology of incretin hormonesCell Metab31536516517403
   PubMed Web of Science ®Google Scholar
• DunningBELigueros-SaylanMD’AlessioDA2006Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetesDiabetologia49suppl 11101Abstract 0174
   Google Scholar
• Eucreas [package insert]2008West Sussex, UKNovartis Europharm
   Google Scholar
• FonsecaVBaronMShaoQDejagerS2008Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusHorm Metab Res404273018401832
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtD2007Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia5011485517387446
   PubMed Web of Science ®Google Scholar
• Galvus [package insert]2008West Sussex, UKNovartis Europharm
   Google Scholar
• GarberAJFoleyJEBanerjiMA2008Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab218[Epub ahead of print]
   Web of Science ®Google Scholar
• GarberAJSchweizerABaronMA2007Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab91667417300592
   PubMed Web of Science ®Google Scholar
• HeYLFlanneryBCampestriniJ2008dEffect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteersCurr Med Res Opin241703918471347
   PubMed Web of Science ®Google Scholar
• HeYLLigueros-SaylanMSunkaraG2008bVildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjectsJ Clin Pharmacol48859517986525
   PubMed Web of Science ®Google Scholar
• HeYLPaladiniSSabiaH2008cBioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjectsInt J Clin Pharmacol Ther462596718538112
   PubMed Web of Science ®Google Scholar
• HeYLSaboRCampestriniJ2007eThe influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptinEur J Clin Pharmacol636778617486328
   PubMed Web of Science ®Google Scholar
• HeYLSaboRCampestriniJ2008aThe effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteersBr J Clin Pharmacol653384617961192
   PubMed Web of Science ®Google Scholar
• HeYLSaboRRiviereGJ2007dEffect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsCurr Med Res Opin231131817519080
   PubMed Web of Science ®Google Scholar
• HeYLSaboRSunkaraG2007fEvaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteersJ Clin Pharmacol47998100417660482
   PubMed Web of Science ®Google Scholar
• HeYLSadlerBMSaboR2007bThe absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipep-tidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersClin Pharmacokinet4678780217713976
   PubMed Web of Science ®Google Scholar
• HeYLSerraDWangY2007cPharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusClin Pharmacokinet465778817596103
   PubMed Web of Science ®Google Scholar
• HeYLWangYBullockJ2007aPharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTTJ Clin Pharmacol476334117442688
   PubMed Web of Science ®Google Scholar
• HinkeSAKühn-WacheKHoffmanT2002Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1Biochem Biophys Res Commun2911302811883961
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMA2006Glycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med35524274317145742
   PubMed Web of Science ®Google Scholar
• MariASallasWMHeYL2005Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesJ Clin Endocrinol Metab9048889415886245
   PubMed Web of Science ®Google Scholar
• MariAScherbaumWANilssonPM2008Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemiaJ Clin Endocrinol Metab93103917925336
   PubMed Web of Science ®Google Scholar
• MathieuCBollaertsK2007Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitorsInt J Clin Pract Suppl154293717593275
   PubMedGoogle Scholar
• MatikainenNManttariSSchweizerA2006Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia4920495716816950
   PubMed Web of Science ®Google Scholar
• MelikianCWhiteTJVanderplasA2002Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther24460711952029
   PubMed Web of Science ®Google Scholar
• MigoyaEMillerJLarsonP2007Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrationsPresented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD)Amsterdam, NetherlandsAbstract 0111
   Google Scholar
• NathanDMBuseJBDavidsonMB2006Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2919637216873813
   PubMed Web of Science ®Google Scholar
• PanCYangWBaronaJP2008Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabet Med254354118341596
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerS2007Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract76132817223217
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaR-P2007bEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab91758517300593
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerS2007aComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetesDiabetes Care302172317259484
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellM2008Effects of the dipeptidyl peptidase inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care3130517947341
   PubMed Web of Science ®Google Scholar
• SaydahSHFradkinJCowieCC2004Poor control of risk factors for vascular disease among adults with previously diagnosed diabetesJAMA2913354214734596
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariA2008aEfficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab106758218248490
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariA2008bEvidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab318[Epub ahead of print].
   Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerS2007Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetesDiabet Med249556117509069
   PubMed Web of Science ®Google Scholar
• SunkaraGSaboRWangY2007Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersJ Clin Pharmacol471152817656620
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group1998Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet352854659742977
   PubMed Web of Science ®Google Scholar
• UtzschneiderKMTongJMontgomeryB2008The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucoseDiabetes Care311081317909087
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPD2007Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetesDiabetes5614758017303799
   PubMed Web of Science ®Google Scholar
• VilsbøllTHolstJJ2004Incretins, insulin secretion and type 2 diabetes mellitusDiabetologia473576614968296
   PubMed Web of Science ®Google Scholar
• YasudaNInoueTNakaguraT2002Enhanced secretion of glucagon-like peptide 1 by biguanide compoundsBiochem Biophys Res Commun2987798412419322
   PubMed Web of Science ®Google Scholar